Immupharma PLC Holding(s) in Company (9558Z)
March 20 2017 - 7:41AM
UK Regulatory
TIDMIMM TIDMAV.
RNS Number : 9558Z
Immupharma PLC
20 March 2017
20 MARCH 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, announces that it has today received a TR-1 by
Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed
at a total of 10,280,516 Ordinary Shares which equates to a current
position in the Company of 7.76% of ImmuPharma's total voting
rights figure of 132,522,985 Ordinary Shares.
Full disclosure of the TR1 is shown below:
1. Identity of the issuer or Immupharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- -------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
----------------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------------------------------------------------
Other (please
specify): CHANGE TO THE NUMBER OF VOTING RIGHTS
IN ISSUE, FOLLOWING THE RECENT PLACING
----------------------------------------------------------- ---------------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- ---------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
Chase (GA Group) Nominees
Limited : 7,361,243*
HSBC Global Custody Nominee
(UK) Limited : 1,606,013*
State Street Nominees Limited
: 200,974*
*denotes direct interest
Chase (GA Group) Nominees
Limited : 409,378
Chase Nominees Limited : 248,294
Vidacos Nominees Limited :
436,614
------------------------------------------------------------- ---------------------------------------------
5. Date of the transaction 16 March 2017
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- ---------------------------------------------
6. Date on which issuer 17 March 2017
notified:
------------------------------------------------------------- ---------------------------------------------
7. Threshold(s) that is/are 7% to 6% Change at Direct
crossed or Interest Level (Box 8A)
reached: (vi, vii)
------------------------------------------------------------- ---------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after
of to the triggering the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------------- -------------------------------- -------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights (x)
Shares Voting shares rights
Rights
------------------- ------------------- ----------- ----------- ---------------------- ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------------- ------------------- ----------- ----------- ---------- ---------- ------- ---------
Ordinary
Shares
GB0033711010 11,169,942 11,169,942 10,262,516 9,168,230 1,094,286 6.92% 0.83%
------------------- ----------- ----------- ---------- ---------- ------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------- ------------------- ------------------------ ---------------------- ------------------
18,000*
RIGHT TO RECALL
LOANED SHARES N/A N/A *DIRECT INTEREST 0.01%
------------------- ------------------- ------------------------ ---------------------- ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
10,280,516 7.76%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
--------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
--------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- ---------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
--------------------------------------------- ---------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- ---------------------------------
13. Additional information: Figures are based the revised
total number of voting rights
of 132,522,985 as per the
recent GBP4.1 Million Fund
Raise via Accelerated Bookbuild
announcement of 10 March
2017.
--------------------------------------------- ---------------------------------
14. Contact name: Neil Whittaker, Aviva plc
--------------------------------------------- ---------------------------------
15. Contact telephone number: 01603 684420
--------------------------------------------- ---------------------------------
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
(NOMAD & Broker)
Patrick Claridge, David Hignell,
Michael Mackintosh, Corporate
Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLFBLFLDXFXBBV
(END) Dow Jones Newswires
March 20, 2017 07:41 ET (11:41 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
